| Literature DB >> 33392820 |
Amira Kohil1, Sara Jemmieh1, Maria K Smatti2, Hadi M Yassine3.
Abstract
Meningitis is a serious condition that affects the central nervous system. It is an inflammation of the meninges, which is the membrane that surrounds both the brain and the spinal cord. Meningitis can be caused by bacterial, viral, or fungal infections. Many viruses, such as enteroviruses, herpesviruses, and influenza viruses, can cause this neurological disorder. However, enteroviruses have been found to be the underlying cause of most viral meningitis cases worldwide. With few exceptions, the clinical manifestations and symptoms associated with viral meningitis are similar for the different causative agents, which makes it difficult to diagnose the disease at early stages. The pathogenesis of viral meningitis is not clearly defined, and more studies are needed to improve the health care of patients in terms of early diagnosis and management. This review article discusses the most common causative agents, epidemiology, clinical features, diagnosis, and pathogenesis of viral meningitis.Entities:
Mesh:
Year: 2021 PMID: 33392820 PMCID: PMC7779091 DOI: 10.1007/s00705-020-04891-1
Source DB: PubMed Journal: Arch Virol ISSN: 0304-8608 Impact factor: 2.685
Epidemiology of viral meningitis in children worldwide
| Country | Years | Number of cases n (%) | Incidence | Common causative agent | Most common clinical manifestation | Reference |
|---|---|---|---|---|---|---|
| Denmark | 1977-2001 | 1642 cases | 38.7 per 100,000 (6-month-old infants) | Mumps and non-polio enteroviruses | - | [ |
| Fiji (South Pacific) | 2004-2007 | 12 (17.1%) | - | EV | Fever | [ |
| USA | 2005-2011 | 7618 cases | - | EV | Fever and headache | [ |
| China | 2013 | 74 (55.2%) | - | EV-71 | Fever and myoclonic seizures | [ |
| England | 2014-2015 | 703 cases | EV = 0.79 per 1000 HPeV = 0.04 per 1000 for | EV and HPeV | Fever and irritability | [ |
Epidemiology of viral meningitis in adults worldwide
| Country | Years | Number of cases n (%) | Common causative agent | Most common clinical manifestation | Reference |
|---|---|---|---|---|---|
| Greece | 2003-2006 | 36 (44.4%) | EV, VZV, and HSV-2 | [ | |
| South Korea | 2008-2013 | 96 (54.2%) | EV and VZV | Headache and fever | [ |
| Italy | 2002-2006 | 162 (80%) | Fever and headache | [ | |
| England | 2011-2014 | 638 (57%) | Non-polio enteroviruses | Headache and photophobia | [ |
| Finland | 1999-2003 | 95 (66%) | EV | Headache and photophobia | [ |
Epidemiology of viral meningitis in the MENA region
| Country | Years | Number of patients with meningitis n (%) | Common causative agent | Most common clinical manifestation | Reference |
|---|---|---|---|---|---|
| Jordan | 1999 | 32 cases | E-9 and Coxsackievirus B4 | Fever and vomiting | [ |
| 2001 | 474 cases | - | Fever | [ | |
| 2014 | 463 cases | - | Fever | [ | |
| Egypt | 2007 | 17 (6.8%) | EV and HSV | - | [ |
| 2010-2012 | 100 cases | EV | Fever and signs of meningeal irritations | [ | |
| Kuwait | 2003-2006 | 387 cases | E-9, E-11 and E-30 | Fever | [ |
| UAE | 2000-2005 | 34 (37%) | - | Fever and neck stiffness | [ |
| Qatar | 2011-2015 | 411 (74.7%) | EV | Fever and headache | [ |
| Palestine | 2013-2014 | 80 (62%) | EV | Fever and vomiting | [ |
| 2012-2015 | 356 cases | EV-B | Fever and headache | [ |
Fig. 1Schematic presentation of the general features of viral meningitis pathogenesis
Fig. 2Echovirus 30 affects the TRIO protein, leading to neural damage and CNS complications.
The most common types of vaccines developed against EV-71
| Type of vaccine | Composition | Advantages |
|---|---|---|
| Virus-like particle (VLP) | SP70 epitope (EV-71) + CVA16 structural protein or SP70 epitope (EV-71) + hepatitis B core antigen | Highly immunogenic with the production of neutralizing antibodies at high titers |
| Recombinant vaccine | Adenovirus (E1/E3 deleted) + EV71 P1 and 3CD genes | Showed neutralization of EV71 B4 and C2 genotypes Reduces the viral load by activating IFN-γ, IL-17, IL-4, and IL-13 |
| Live attenuated vaccine | Experiments were done using EV71(S1-3′) from genotype A | Showed neutralizing activities against A, B1, B4, C2, and C4 |